{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.8"}]}],"title":"Weekly Bortezomib"},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.5"}]}],"title":"Twice-Weekly Bortezomib"}],"denoms":[{"counts":[{"groupId":"OG000","value":"54"},{"groupId":"OG001","value":"0"}],"units":"Participants"}],"description":"Maximum tolerated dose of Bortezomib in combination with Rituximab, Cyclophosphamide and Prednisone in Phase I participants","groups":[{"description":"Patients receive cyclophosphamide IV and rituximab IV on day 1, oral prednisone on days 2-6, and bortezomib IV (at the MTD determined in phase I) on days 2, 5, 9, and 12. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.\n\nrituximab: Given IV\n\nbortezomib: Given IV\n\ncyclophosphamide: Given IV\n\nprednisone: Given orally","id":"OG000","title":"Arm I"},{"description":"Patients receive cyclophosphamide IV and rituximab IV on day 1, oral prednisone on days 2-6, and bortezomib IV (at the MTD determined in phase I) on days 2 and 8. Treatment repeats every 21 days for up to 8 courses in the absence of disease progression or unacceptable toxicity.\n\nrituximab: Given IV\n\nbortezomib: Given IV\n\ncyclophosphamide: Given IV\n\nprednisone: Given orally","id":"OG001","title":"Arm II"}],"paramType":"NUMBER","populationDescription":"This outcome is only applicable for Phase I portion of the study. The purpose of the Phase I portion of the study is to determine the Maximum Tolerated Dose and for this reason the results are not separated by dose level.","reportingStatus":"POSTED","timeFrame":"2 years","title":"Maximum Tolerated Dose","type":"PRIMARY","unitOfMeasure":"mg/m^2 of Bortezomib"}